Mario Hassi retuiteado
📢 Study Highlights: PSA Decline as a Predictor in mHSPC Treatment
A retrospective multicenter study analyzed 633 patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with apalutamide (2018-2023). PSA response at 3 months was strongly linked to outcomes:
✅ Complete Response (PSA ≤0.02 ng/ml): 27% of patients, 92% radiologic progression-free survival (rPFS) at 24 months.
⚠️ Partial Response (PSA >0.02-0.2 ng/ml): 42% of patients, 86% rPFS at 24 months.
❌ Incomplete Response (PSA >0.2 ng/ml): 31% of patients, 63% rPFS at 24 months, with nearly 50% progressing within 2 years.
🔑 Predictive factors for a complete PSA response:
•Use of next-generation imaging.
•PSA <50 ng/ml at diagnosis.
💡 Implications: Early PSA response after 3 months of treatment provides a powerful prognostic tool to guide therapy for mHSPC. Heterogeneity among patients and data quality remain key limitations
pubmed.ncbi.nlm.nih.gov/39474116/
English
